TL;DR

  • Two unrelated FDA peptide actions happened five days apart in July 2026 and are often reported as one event.

  • On 23 and 24 July, the Pharmacy Compounding Advisory Committee recommended six of seven peptides for the Section 503A Bulks List. Emideltide was rejected. Every vote was tied to one specific medical use.

  • The vote was advisory only. None of the peptides has been added to the Section 503A Bulks List, so 503A compounding remains unauthorized.

  • FDA staff recommended against all seven, citing limited human evidence, safety concerns, and quality standard issues. Eight committee members were newly appointed in June 2026, with reported peptide industry ties.

  • Any access would still require FDA action. Formal rulemaking could take 12 to 24 months, while enforcement discretion could be faster.

  • On 28 July, the FDA separately updated draft guidances for nine approved peptide drugs, including semaglutide and tirzepatide, and withdrew its 2021 synthetic peptide guidance for revision.

  • If access eventually changes, these peptides would remain prescription-only, compounded, paid out of pocket, and without evidence-based professional dosing guidelines.

What Did the FDA Do About Peptides in July 2026?

The FDA took two separate actions in late July 2026. The first was an advisory committee vote on 23 and 24 July concerning whether compounding pharmacies should be permitted to manufacture seven unapproved peptides. The second was the publication on 28 July of 17 revised draft product-specific guidances covering nine approved peptide and protein drugs, including semaglutide and tirzepatide.

The two actions share a subject and a week. They share no compounds, no regulatory pathway, and no decision-making body. Coverage that treats them as one event misstates both. The first concerns substances with no FDA approval. The second concerns generic versions of drugs already on the market.

What Is a Peptide?

A peptide is a short chain of amino acids, shorter than a protein, that functions in the body as a signalling molecule. Insulin is a peptide. So are the GLP-1 receptor agonists semaglutide and tirzepatide. The category spans approved medicines subjected to large controlled trials and experimental substances with no human data.

The regulatory question is not whether peptides work as a class. It is whether a specific sequence, produced by a specific method, has been characterised well enough to be made safely and used predictably. The seven substances reviewed in July 2026 sit at the untested end of that range.

503 A Bulks List by FDA and difference with 503 B - ONPEPS

What Is the Section 503A Bulks List?

Section 503A of the Federal Food, Drug, and Cosmetic Act governs compounding by state-licensed pharmacies. The 503A Bulks List is the register of bulk drug substances those pharmacies may lawfully use when a substance has no applicable United States Pharmacopeia monograph and is not a component of an approved drug.

Placement on the list does not constitute drug approval. It establishes that a substance may be used as a raw ingredient in a compounded preparation dispensed against a prescription. The list is codified at 21 CFR 216.23 and can only be amended through formal rulemaking.

How 503A Differs from 503B

A 503A pharmacy compounds against an individual prescription for a named patient and is regulated primarily by state boards of pharmacy. A 503B outsourcing facility manufactures in batches without patient-specific prescriptions and registers with the FDA under federal current good manufacturing practice requirements. The July vote concerned the 503A list only. A substance permitted for 503A compounding is not thereby permitted for large-scale 503B production.

Which Peptides Did the Advisory Committee Vote On?

The Pharmacy Compounding Advisory Committee met at the FDA White Oak Campus in Silver Spring, Maryland, in Building 31, Room 1503. Each substance was evaluated in both free base and acetate forms, and each vote was tied to one specific reviewed indication rather than to general use.

The uses the FDA reviewed, per the agency meeting agenda published 22 July 2026:

  • BPC-157, for ulcerative colitis. Recommended 8 to 6, with 1 abstention.

  • KPV, for wound healing and inflammatory conditions. Recommended 8 to 6, with 1 abstention.

  • TB-500, for wound healing. Recommended 8 to 6, with 1 abstention.

  • MOTS-c, for obesity and osteoporosis. Recommended 7 to 5, with 2 abstentions.

  • Semax, for cerebral ischemia, migraine and trigeminal neuralgia. Recommended 8 to 5, with 1 abstention, on 24 July.

  • Epitalon, for insomnia. Recommended 7 to 4, with 1 abstention, on 24 July.

  • Emideltide, also called delta sleep-inducing peptide, for opioid withdrawal, chronic insomnia and narcolepsy. Rejected 7 to 6, with 1 abstention.

The indication tie matters. A favourable vote on BPC-157 covers ulcerative colitis. It carries no finding regarding tendon repair, joint recovery or the musculoskeletal uses that drive consumer demand.

No. Neither substance is an approved drug, and neither has been added to the Section 503A Bulks List. No new compounding authority has been granted.

Advisory committee recommendations are non-binding. The FDA generally follows them but is not obliged to, and has departed from committee advice before. The recommendation is an input to a decision the agency has not yet made.

New Rules Before Compounded Peptides Become Legal FDA rulings 2026 by ONPEPS

Two routes exist. Which one the FDA takes determines whether access arrives in months or in years.

Route One: Formal Notice-and-Comment Rulemaking

The standard path under the Administrative Procedure Act requires the FDA to publish a notice of proposed rulemaking, open a public comment period of 60 to 90 days, review submissions, obtain Office of Management and Budget review, then publish a final rule amending 21 CFR 216.23. Estimates from compounding-sector attorneys place this at 12 to 24 months from the vote. No statutory deadline governs it.

Route Two: Interim Enforcement Discretion

The FDA can place substances in Category 1 of the interim compounding policy, or state that it will not pursue enforcement against 503A pharmacies compounding them, while rulemaking proceeds. This route is measured in weeks to months. Jesse Dresser, a partner at Frier Levitt representing compounding pharmacies, told NPR in August 2026 that a traditional rulemaking path would be surprising and that faster options are likely to be used.

Health and Human Services Secretary Robert F. Kennedy Jr. has publicly supported wider peptide access, which raises the probability of the faster route. A decision to bypass standard rulemaking would likely attract legal challenge.

Why Did FDA Scientists Recommend Against All Seven Peptides?

Agency reviewers opposed every substance under consideration. Their objections fell into three categories.

Insufficient Human Evidence

FDA briefing documents concluded that available studies were short in duration, small in sample size, and inadequate to establish safety or effectiveness for the reviewed indications. Five trials of BPC-157 were assessed and found insufficient. For several substances, reviewers located no published human clinical studies at all.

Immunogenicity and Anaphylaxis Risk

Synthetic peptides that mimic naturally occurring molecules can provoke a durable immune response. Annie De Groot, president of EVA Therapeutics, cited synthetic erythropoietin as a precedent, and pointed to the 2013 case of taspoglutide, where manufacturing errors in the amino acid sequence produced anaphylaxis symptoms during a phase 3 diabetes trial [De Groot, EVA Therapeutics, 2026].

Substance Identity and Manufacturing Control

Russell Wesdyk, an FDA official presenting at the meeting, described defining the substances as a foundational challenge, stating that compounds sold under a single peptide name vary considerably in chemical composition. His position was that quality standards cannot be written for a substance that has not been consistently defined. Several of the peptides also dissolve poorly in water, which introduces dose variability between injections.

Who Sat on the Advisory Committee?

The committee roster was reconstituted before the meeting. Eight new members were appointed in June 2026. Reporting indicates many committee members have professional or financial ties to clinics, telehealth companies, or businesses that sell or prescribe peptides. The Department of Health and Human Services stated that all members completed standard ethics and conflict vetting.

Dissent came from academic and clinical members. Elizabeth Rebello, an anaesthesiologist at the University of Texas MD Anderson Cancer Center, stated after a no vote that she was concerned the committee was responding to market-induced demand rather than a decision based in solid science [Rebello, MD Anderson, 2026]. Brian Lee, associate professor at the Keck School of Medicine of the University of Southern California, stated that the endorsement could be potentially harmful [Lee, Keck School of Medicine, 2026].

What Changed for Peptides in April 2026 by onpeps

What Changed for Peptides in April 2026?

The July vote was not the first regulatory movement. In 2023, the FDA placed these seven peptides and twelve other substances in Category 2 of its interim compounding policy, the designation for substances presenting significant safety risk. In April 2026, the agency withdrew the seven from that high-risk list.

That withdrawal made the substances eligible for evaluation. It did not authorise compounding. Secretary Kennedy characterised the move as one that would shift demand away from the black market. The sequence is therefore three steps: removal from Category 2 in April, advisory recommendation in July, and rulemaking still pending.

What Was the Separate 28 July Generic Guidance Action?

On 28 July 2026, the FDA published 17 revised draft product-specific guidances for peptide products, announced in the Federal Register on 29 July at 91 FR 47834 under docket FDA-2007-D-0369. Product-specific guidances instruct generic manufacturers on bioequivalence study design for abbreviated new drug applications.

The guidances cover nine active ingredients across 17 approved products: calcitonin salmon, dasiglucagon hydrochloride, glucagon, liraglutide, pegcetacoplan, semaglutide, teriparatide, tirzepatide and vosoritide. Brand references include OZEMPIC, WEGOVY, MOUNJARO, ZEPBOUND, VICTOZA, SAXENDA, FORTEO, BAQSIMI and VOXZOGO. Public comments close 28 September 2026.

The revisions address five areas: submission of recombinantly, synthetically or semi-synthetically produced peptides as abbreviated new drug applications, innate immune response testing, impurity thresholds, higher order structure assessment, and biological activity assessment.

The Withdrawn 2021 Guidance

On the same day, the FDA withdrew the May 2021 guidance titled ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin, stating it no longer reflects current scientific thinking. The agency intends to reissue a revised version during 2026. That guidance governed synthetic generic versions of peptide drugs originally produced through recombinant DNA methods. The notice does not indicate whether the replacement will be more or less permissive.

How Do the Two July Actions Differ?

The advisory committee vote concerns compounding eligibility, decided by an external panel, governed by Section 503A, and resolved through rulemaking. The guidance action concerns bioequivalence methodology, issued by the Center for Drug Evaluation and Research, governed by the abbreviated new drug application pathway, and resolved through a comment docket.

No compound appears in both. Any article linking one to the other has conflated separate regulatory tracks.

Why Did Demand Outpace the Evidence?

The gray market expanded after the 2023 Category 2 designation removed any lawful compounding route. Supply moved to vendors selling research-grade material under disclaimers stating the product is for laboratory use and not for human consumption. Buyers obtain vials of unverified purity and concentration and determine dosing from community forums rather than clinical protocols.

Promotion accelerated the shift. Peptides are marketed across the wellness and longevity sector for injury recovery, muscle growth, fat loss and athletic performance, frequently combined into multi-substance stacks. None of these uses corresponds to an indication the FDA evaluated.

Who Has a Commercial Interest in the Outcome?

Direct-to-consumer telehealth companies, compounding pharmacies, medical spas and longevity clinics stand to gain from a regulated pathway. Reporting identifies telehealth firms among those lobbying for eased restrictions, with the addressable market estimated in the billions of dollars. Several committee members work in or for that sector.

The counter-position is held by pharmacy and medical professional bodies. The American Pharmacists Association submitted a public comment recommending against compounding on evidentiary grounds. Brigid Groves, vice president of professional affairs at the American Pharmacists Association, stated that safe clinical recommendations require good research and education on these substances [Groves, American Pharmacists Association, 2026].

Do State Rules Change Anything?

Compounding is enforced jointly. Federal rules establish which substances may be compounded, and state boards of pharmacy regulate how 503A facilities operate within each state. A federal listing does not compel a state to permit local dispensing, and states have issued their own notices concerning research-grade peptide sales. Practitioners should confirm state-level position separately from federal status.

Future of Peptides as a result of FDA Rulings in 2026 by onpeps.com

What Does This Mean for Cost, Access and Timing?

If the FDA acts on the recommendation, these peptides will require a prescription. They will be dispensed by compounding pharmacies rather than retail chains. Scott Brunner, chief executive of the Alliance for Pharmacy Compounding, indicated that pharmacies will need time to source active ingredients once permitted, estimating two to nine months depending on the substance [Brunner, Alliance for Pharmacy Compounding, 2026].

Compounded preparations generally fall outside standard pharmacy benefit coverage, so out-of-pocket payment is likely to continue. Reported clinic pricing for peptides currently ranges from 60 to 200 US dollars per month. A regulated supply chain introduces verified sterility, known concentration and prescriber oversight, none of which the research-chemical market provides.

Professional guidance remains absent. No major medical association has published evidence-based protocols for dosing, cycling, or patient selection for these substances.

Frequently Asked Questions

Is BPC-157 FDA Approved?

No. BPC-157 has never been approved as a drug in the United States. Compounding eligibility, which the July 2026 vote addressed, is a lower evidentiary standard than drug approval and remains unresolved.

Which Peptides Are FDA Approved?

Approved peptide drugs include semaglutide, tirzepatide, liraglutide, tesamorelin, bremelanotide, and insulin. None of the seven substances reviewed in July 2026 is among them.

Can BPC-157 Be Carried on Domestic Flights?

No federal rule specifically addresses this. The substance is not a controlled substance, but it is not an approved drug and cannot be lawfully dispensed for human use, so it carries no prescription label. Individuals should consult a licensed attorney regarding personal legal exposure.

Are These Peptides Banned in Sport?

BPC-157 and TB-500 are classified as prohibited substances by international sports authorities. A change in United States compounding status does not alter anti-doping classification.

When Will the FDA Decide?

The agency stated at the meeting that it would weigh committee recommendations against staff scientific assessment and public comment. The Pharmacy Compounding Advisory Committee is scheduled to reconvene in February to consider additional peptides.

Resources: